A phase 1/2 trial reveals sacituzumab tirumotecan shows manageable toxicity and promising antitumor activity in patients with ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

A phase 3 study shows Cylembio combined with pembrolizumab improves progression-free survival in advanced melanoma, ...

New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic ...

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal ...

Marwan G. Fakih, MD, discusses barriers that create treatment differences in metastatic colorectal cancer for community oncologists.

Enzalutamide's efficacy is supported by preference studies and a MAIC, helping doctors and patients make informed treatment ...

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

Enzalutamide and other ARPIs are key in treating metastatic prostate cancer by blocking androgen receptors, improving patient ...

The NCCN added critical guidance on Lambert-Eaton myasthenic syndrome to its recommendation for the diagnosis and treatment ...

A statistical analysis (MAIC) of the ARCHES and ARANOTE studies suggests enzalutamide is more effective at delaying disease progression.